Johnson & Johnson has recalled lots of its Simponi injections for possible substandard dosage of its arthritis treatment, according to a Reuters news report. A Johnson & Johnson spokesperson said ...
NEW YORK, Oct 17 (Reuters) - Johnson & Johnson's new rheumatoid arthritis drug, Simponi, when used in combination with the common treatment methotrexate was significantly more effective at inhibiting ...
Findings showed 32% of patients achieved clinical remission (Mayo score ≤2 points, with no individual subscore >1) at week 6. The Food and Drug Administration (FDA) has expanded the approval of ...
The confirmatory clinical safety and efficacy study for AVT05, biosimilar candidate to Simponi ® and Simponi Aria ® (golimumab), met its primary endpoint in patients with moderate to severe rheumatoid ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results